title: [A case of tuberculous peritonitis in a hemodialysis patient revealed by severe diarrhea and stomachache].
abstract: A 53-year-old woman was admitted to our hospital due to abdominal pain, diarrhea, and shunt occlusion caused by dehydration. She had undergone hemodialysis due to diabetic nephropathy over a ten-year period. She was hospitalized again with fever and a persistent high serum CRP level. We started antibiotic administration using cefotiam hexetil hydrochloride because of ascites and peritoneum thickening observed by abdominal computed tomography. Although her symptoms, such as abdominal pain and diarrhea, improved after the administration of antibiotics, the ascites and the peritoneum thickening did not improve. On the fourth hospital day, we attempted ascites aspiration to investigate the etiology of the peritonitis. Cytological examination suggested tuberculous peritonitis because of predominant macrophage cell proliferation, a high level of ADA concentration, and a high level of CA125 of ascites. Although QuantiFERON-tuberculosis (QFT) and the Gaffky scale were negative, we started multidrug therapy (isoniazid + rifampicin + pyrazinamide + ethambutol) on the 20th hospital day. She was finally diagnosed as mycobacterium tuberculous peritonitis based on biopsy of the tissue of the ileum and the results of colonoscopy. Administration of antituberculosis chemotherapy improved abdominal fullness and ascites and the patient was discharged on the 97th hospital day. Moreover Kuno et al. reported that serum soluble interleukin-2 receptor(sIL-2R) and CA-125 levels can be used to monitor the response to anti-tuberculosis treatment. In this case, we use these markers to monitor the response to treatment. We experienced a case of tuberculous peritonitis undergoing hemodialysis. Tuberculosis should be suspected when patients undergoing dialysis have long-term fever of unknown etiology. There are many reports stating that the sensitivity and specificity of QuantiFERON-tuberculosis (QFT) and sputum culture are low in latent tuberculosis infection of dialysis patients. Accordingly it is necessary to diagnose mycobacterium tuberculous peritonitis comprehensively by the clinical symptoms and image analysis.
authors: Department of Nephrology, Ohmihachiman Community Medical Center, Shiga, Japan.
authors: Masayuki
authors: M
authors: Hara
authors: Tsuguru
authors: T
authors: Hatta
authors: Mai
authors: M
authors: Ohtani
authors: Hiroyoshi
authors: H
authors: Segawa
authors: Risa
authors: R
authors: Ueno
authors: Katsunori
authors: K
authors: Sawada
mesh_terms: D015746:Abdominal Pain / Q000150:complications*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D003937:Diagnosis, Differential; D003967:Diarrhea / Q000150:complications*; D004338:Drug Combinations; D004977:Ethambutol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008875:Middle Aged; D014395:Peritonitis, Tuberculous / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D011718:Pyrazinamide / Q000627:therapeutic use*; D015375:Receptors, Interleukin-2 / Q000097:blood; D006435:Renal Dialysis / Q000379:methods; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents; D015415:Biomarkers; D018394:CA-125 Antigen; D004338:Drug Combinations; D015375:Receptors, Interleukin-2; C087181:isoniazid, pyrazinamide, rifampin drug combination; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin